Last Updated on December 24, 2023 by The Health Master
USFDA Approval
The pharmaceutical industry is abuzz with the recent news of Glenmark Pharmaceuticals receiving final USFDA approval from the United States Food & Drug Administration (USFDA) for Fluphenazine Hydrochloride Tablets USP in various strengths, including 1 mg, 2.5 mg, 5 mg, and 10 mg.
This approval marks a significant milestone for Glenmark and the generic pharmaceutical sector as a whole.
Approval Details
1. USFDA Nod for Fluphenazine Hydrochloride Tablets USP
Glenmark’s Fluphenazine Hydrochloride Tablets have garnered the final stamp of approval from the USFDA.
This recognition positions the medication as a generic alternative to Prolixin Tablets, initially developed by Apothecon.
Understanding the specifics of this approval sheds light on the pathway for the drug’s availability in the market.
2. Distribution Plans by Glenmark Pharmaceuticals US
The responsibility of distributing these newly approved tablets in the US market falls on Glenmark Pharmaceuticals US.
Delving into the intricacies of the distribution process provides insights into the accessibility of this medication for consumers.
Market Impact
1. Insights from IQVIA Sales Data
IQVIA sales data for the 12‐month period ending September 2023 reveals that Prolixin Tablets, in varying strengths, achieved annual sales of approximately $18.1 million.
Analyzing the impact of this data on the market and Glenmark Pharmaceuticals elucidates the competitive landscape.
2. Competitive Landscape and Market Growth
Glenmark’s entrance into the market with Fluphenazine Hydrochloride Tablets prompts an exploration of its competitive positioning.
Additionally, the potential growth in the market due to this USFDA approval is a factor worth considering.
Glenmark’s Portfolio
A. Current Product Lineup
Glenmark boasts a portfolio of 189 products authorized for distribution in the U.S. marketplace.
Understanding the diversity and scale of their current offerings provides context for the significance of the recent USFDA approval.
B. ANDAs Pending Approval
With 50 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA, Glenmark anticipates further expansions in its portfolio.
Assessing the potential contributions of these pending approvals adds another layer to the company’s growth strategy.
FAQs
- Is Fluphenazine Hydrochloride Tablets the only USFDA-approved medication by Glenmark Pharmaceuticals?
- No, Glenmark has a diverse portfolio of 189 products authorized for distribution in the U.S. market.
- What does IQVIA sales data reveal about Prolixin Tablets?
- IQVIA sales data for the 12-month period ending September 2023 indicates approximately $18.1 million in annual sales for Prolixin Tablets.
- Who will be responsible for distributing Fluphenazine Hydrochloride Tablets in the US?
- Glenmark Pharmaceuticals US will handle the distribution of the newly approved tablets in the US market.
- How many ANDAs are pending approval for Glenmark Pharmaceuticals?
- Currently, Glenmark has 50 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.
- What is the significance of the USFDA approval for Fluphenazine Hydrochloride Tablets?
- The USFDA approval positions Glenmark Pharmaceuticals as a key player in the generic pharmaceutical sector, offering an alternative to Prolixin Tablets in various strengths.
USFDA Approval granted for this Revolutionary Weight Loss Drug
USFDA Approval granted for Sitagliptin and Metformin HCL Tablets
USFDA approval granted for Esomeprazole Magnesium Capsules: Granules
USFDA Approval: USFDA Approval granted for Apremilast Tablets
USFDA tentative approval granted for Apalutamide tablets
USFDA approval granted for this inflammatory bowel disease drug
NPPA fixed retail price of 29 formulations: October 2023
This lung cancer drug gets European Medicines Agency’s backing
Torrent and Zydus Join Forces to Combat Liver Disorders
17 Crore: Most costly Lifeline injection for SMA Afflicted Children
USFDA issues EIR For Piramal Pharma Bethlehem Facility
Drug recall: These Eye Drops recalled due to Potential Risk of Eye Infections
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
